FDA is advised to reject wider use of Amgen's Xgeva

02/8/2012 | Reuters

An expert panel urged the FDA not to approve Amgen's Xgeva for delaying the spread of prostate cancer to the bone, saying the drug's benefits do not outweigh the risk of developing osteonecrosis of the jaw. Xgeva provides a meaningful benefit, and is being tested against other cancers, including breast, lung and multiple myeloma, Amgen said. The FDA will issue a final ruling by April 26.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Actuarial Services, Government Programs
PacificSource
OR
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Counsel I – Clinical Contracts
Gilead Sciences
Foster City, CA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Vice President, Idaho Regional Director
PacificSource
Boise, ID